Published in Genomics and Genetics Weekly, October 5th, 2001
"Lexicon has assembled the expertise to rapidly implement an integrated gene-to-lead drug discovery platform," said Arthur T. Sands, MD, PhD, president and chief executive officer of Lexicon. By combining our in vivo mammalian validated targets with Lexicon Pharmaceuticals' chemical approaches to discover small-molecule drugs, the company is well-positioned to capture significantly higher value from the drug targets it discovers, noted Dr. Sands.
To facilitate these initiatives, S. David Kimball, PhD, has joined Lexicon as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly